# Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

> **NCT07038356** · PHASE3 · RECRUITING · sponsor: **Christian Schulze** · enrollment: 536 (estimated)

## Conditions studied

- Acute Decompensated Heart Failure (ADHF)

## Interventions

- **DRUG:** Empagliflozin 10 MG Oral Tablet [Jardiance]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07038356
- **Lead sponsor:** Christian Schulze
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 536 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038356, "Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07038356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*